- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
- Conditions
- AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
- Interventions
- Alfilbercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 51
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- Neovascular Polypoidal Choroidal Vasculopathy
- Interventions
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Diabetic Macular Edema
- Interventions
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Intravitreal Aflibercept injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • McAllen, Texas
- Conditions
- Choroidal Neovascularization, Presumed Ocular Histoplasmosis
- Interventions
- EYLEA (Aflibercept) intravitreal injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- St Louis, Missouri
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Radiation Retinopathy, Macular Edema
- Interventions
- Aflibercept every 2 months, Aflibercept monthly
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Houston, Texas
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Bakersfield, California • Encino, California • Glendale, California + 49 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 2.0 aflibercept, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
- Conditions
- Retinal Hemangioma
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Glendale, California • Pasadena, California • St. Petersburg, Florida + 6 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Macular Edema, Retinal Artery Macroaneurysm
- Interventions
- aflibercept
- Drug
- Lead sponsor
- Kamal Kishore, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fovista®, bevacizumab, ranibizumab, aflibercept
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
- Conditions
- Macular Edema With Central Retinal Vein Occlusions
- Interventions
- Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Pattern Dystrophy of Macula
- Interventions
- aflibercept
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more